CFA
AVXL icon

Cahill Financial Advisors’s Anavex Life Sciences AVXL Stock Holding History

Cahill Financial Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,500
Closed -$63K – 262
2021
Q3 		$63K Buy
+3,500
New +$69.7K 0.01% 311

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cahill Financial Advisors's AVXL Position: Q4 2021 in Review

Cahill Financial Advisors sold out of Anavex Life Sciences (AVXL) in Q4 2021, closing a stake of 3,500 shares — an estimated $63K sold.

Cahill Financial Advisors first reported a position in AVXL in Q3 2021 and held it in 1 quarter. The position peaked at $63K in Q3 2021. 149 funds tracked by Wall St. Rank hold AVXL as of Q4 2021.

  • Cahill Financial Advisors reported no remaining Anavex Life Sciences position as of Q4 2021 after selling out during the quarter.
  • Cahill Financial Advisors sold 3,500 Anavex Life Sciences shares in Q4 2021, an estimated $63K.
  • Cahill Financial Advisors first reported a position in Anavex Life Sciences in Q3 2021 and held it in 1 quarter.
  • Cahill Financial Advisors's Anavex Life Sciences position peaked at $63K in Q3 2021.
  • 149 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2021.

Based on Cahill Financial Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.